PT2318033T - Composições para o tratamento de dor e/ou inflamação - Google Patents

Composições para o tratamento de dor e/ou inflamação

Info

Publication number
PT2318033T
PT2318033T PT09777419T PT09777419T PT2318033T PT 2318033 T PT2318033 T PT 2318033T PT 09777419 T PT09777419 T PT 09777419T PT 09777419 T PT09777419 T PT 09777419T PT 2318033 T PT2318033 T PT 2318033T
Authority
PT
Portugal
Prior art keywords
inflamation
pain
compositions
treatment
Prior art date
Application number
PT09777419T
Other languages
English (en)
Inventor
Van Den Nest Wim
FERNÁNDEZ CARNEADO Jimena
Ponsati Obiols Berta
Carreno Serraima Cristina
Ferrer Montiel Antonio
Camprubi Robles Maria
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of PT2318033T publication Critical patent/PT2318033T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
PT09777419T 2008-07-24 2009-07-24 Composições para o tratamento de dor e/ou inflamação PT2318033T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802210A ES2356883B1 (es) 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación.

Publications (1)

Publication Number Publication Date
PT2318033T true PT2318033T (pt) 2019-01-24

Family

ID=41462205

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09777419T PT2318033T (pt) 2008-07-24 2009-07-24 Composições para o tratamento de dor e/ou inflamação

Country Status (24)

Country Link
US (2) US20110206752A1 (pt)
EP (1) EP2318033B8 (pt)
JP (1) JP5920916B2 (pt)
KR (1) KR20110056491A (pt)
CN (1) CN102164610B (pt)
AR (1) AR072610A1 (pt)
AU (1) AU2009273471C1 (pt)
BR (1) BRPI0911743B1 (pt)
CA (1) CA2731880C (pt)
CY (1) CY1121125T1 (pt)
DK (1) DK2318033T3 (pt)
ES (2) ES2356883B1 (pt)
HR (1) HRP20190059T1 (pt)
HU (1) HUE042083T2 (pt)
IL (1) IL210810B (pt)
LT (1) LT2318033T (pt)
MX (1) MX2011000868A (pt)
PL (1) PL2318033T3 (pt)
PT (1) PT2318033T (pt)
RU (1) RU2515054C2 (pt)
SG (1) SG192548A1 (pt)
SI (1) SI2318033T1 (pt)
TR (1) TR201900542T4 (pt)
WO (1) WO2010009892A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
EP3415157B1 (en) 2011-10-28 2020-09-16 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
CN104039339B (zh) 2011-11-07 2016-01-20 格瑞复斯（武汉）生化科技股份有限公司 肽类化合物作为神经递质分泌抑制剂
US9687669B2 (en) 2011-11-09 2017-06-27 John Stephan Wearable light therapy apparatus
EP2800758B1 (en) * 2012-01-03 2018-08-01 NeoStrata Company, Inc. N-acylpeptide derivatives and their uses
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) * 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
RU2580280C2 (ru) * 2014-07-08 2016-04-10 Общество с ограниченной ответственностью "НИТРОЗДРАВ" Композиция для местного применения для снижения или снятия болевого синдрома
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20190083809A1 (en) 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
CN110191895A (zh) * 2016-11-30 2019-08-30 路博润先进材料公司 可用于处理和/或护理皮肤、毛发、指甲和/或粘膜的化合物
JP7100390B2 (ja) * 2017-09-18 2022-07-13 エニジェン カンパニー．，リミテッド． 活性物質－ヘキサペプチド複合体、及びこれを含む化粧料組成物
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US11975055B2 (en) 2018-05-21 2024-05-07 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
JP2021527085A (ja) 2018-06-13 2021-10-11 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 神経細胞エキソサイトーシスに対して阻害活性を有するペプチド
EP3937957A1 (en) 2019-03-14 2022-01-19 OM Pharma SA Process for making stable bacterial extracts and their use as pharmaceuticals
JP7349052B2 (ja) 2019-06-24 2023-09-22 湖南方升泰医薬科技有限公司 金属錯体の新規応用
CN115583988B (zh) * 2022-10-14 2023-08-18 深圳市维琪科技股份有限公司 合成肽及其组合物和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DK0758900T3 (da) * 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP1856139B1 (en) * 2005-03-03 2011-04-27 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
WO2007071448A2 (en) * 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
KR20090041066A (ko) * 2007-10-23 2009-04-28 성균관대학교산학협력단 신경전달물질 배출을 조절하는 합성 펩타이드

Also Published As

Publication number Publication date
US20110206752A1 (en) 2011-08-25
MX2011000868A (es) 2011-06-09
AU2009273471C1 (en) 2014-08-21
EP2318033B1 (en) 2018-10-17
BRPI0911743B1 (pt) 2021-11-16
TR201900542T4 (tr) 2019-02-21
EP2318033A2 (en) 2011-05-11
CA2731880A1 (en) 2010-01-28
KR20110056491A (ko) 2011-05-30
WO2010009892A8 (en) 2011-02-24
HRP20190059T1 (hr) 2019-03-08
AU2009273471B2 (en) 2014-04-17
DK2318033T3 (en) 2019-02-04
ES2714357T3 (es) 2019-05-28
SG192548A1 (en) 2013-08-30
BRPI0911743A2 (pt) 2015-07-07
WO2010009892A3 (en) 2010-05-14
CN102164610A (zh) 2011-08-24
IL210810B (en) 2018-04-30
ES2356883A1 (es) 2011-04-14
RU2011105280A (ru) 2012-08-27
EP2318033B8 (en) 2019-02-27
WO2010009892A2 (en) 2010-01-28
PL2318033T3 (pl) 2019-04-30
US20190184054A1 (en) 2019-06-20
JP2011528678A (ja) 2011-11-24
SI2318033T1 (sl) 2019-02-28
AR072610A1 (es) 2010-09-08
JP5920916B2 (ja) 2016-05-18
RU2515054C2 (ru) 2014-05-10
LT2318033T (lt) 2019-02-11
IL210810A0 (en) 2011-04-28
AU2009273471A1 (en) 2010-01-28
HUE042083T2 (hu) 2019-06-28
CA2731880C (en) 2016-12-13
CN102164610B (zh) 2014-04-09
CY1121125T1 (el) 2019-12-11
ES2356883B1 (es) 2012-02-22

Similar Documents

Publication Publication Date Title
HRP20190059T1 (hr) Pripravci za liječenje boli i/ili upale
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
EP2125855A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
EP2317931A4 (en) TISSUE MODIFYING DEVICES AND APPLICATION METHOD THEREFOR
EP2212440A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF ADENOCARCINOMES OF DISHES
HK1159498A1 (en) Methods and compositions for the treatment of cancer
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
GB0718446D0 (en) Compositions and methods for the treatment of infection
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1173379A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
IL187405A0 (en) Methods and compositions for the treatment of pain
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
EP2300044A4 (en) METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES
PT2637974T (pt) Composição multifuncional para o tratamento de desinfecção da água e utilização desta composição
GB0714500D0 (en) composition and treatment
ZA200710476B (en) Methods and compositions for the treatment of pain
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
EP2276502A4 (en) COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROLOGICAL INJURIES AND ASSOCIATED METHODS OF USE
GB0820986D0 (en) The treatment of inflammatory disorder and pain